Statera Biopharma, Inc. Files Form 12b-25
March 31 2022 - 4:05PM
Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera
Biopharma”), a leading biopharmaceutical company creating
next-generation immune therapies that focus on immune restoration
and homeostasis, today announced that the Company has filed a Form
12b-25 with the U.S. Securities and Exchange Commission to extend
until April 15, 2022 the due date for filing the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2021.
Statera Biopharma has been unable to complete
its financial statements for the full year 2021 due to a delay
experienced in completing its financial statements and other
disclosures in the Annual Report. As a result, the Company is still
in the process of compiling required information to complete the
Annual Report and its independent registered public accounting firm
requires additional time to complete its audit of the financial
statements for the period ended December 31, 2021 to be included in
the Annual Report. The Company anticipates that it will file the
Annual Report no later than 15 calendar days following the
prescribed due date or by April 15, 2022.
As a result of today’s announcement, the Company
postponed its conference call and webcast to discuss its financial
results for full year 2021. Details for the rescheduled conference
call and webcast will be announced at a later date.
About Statera Biopharma,
Inc.Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a
clinical-stage biopharmaceutical company developing novel
immunotherapies targeting autoimmune, neutropenia/anemia, emerging
viruses and cancers based on a proprietary platform designed to
rebalance the body’s immune system and restore homeostasis. Statera
Biopharma has a large platform of toll-like receptor (TLR) agonists
with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod
and GP532. TLRs are a class of protein that plays a key role in the
innate immune system. Statera Biopharma is developing therapies
designed to directly elicit within patients a robust and durable
response of antigen-specific killer T-cells and antibodies, thereby
activating essential immune defenses against autoimmune,
inflammatory, infectious diseases, and cancers. Statera Biopharma
has clinical programs for Crohn’s disease (STAT-201), hematology
(Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205)
in addition to potential expansion into fibromyalgia and multiple
sclerosis. To learn more about Statera Biopharma, please visit
www.staterabiopharma.com.
Forward Looking Statements:
This press release contains forward-looking statements that involve
risks and uncertainties. All statements other than statements of
current or historical fact contained in this press release,
including statements regarding the Company’s expected clinical
development timeline for the Company’s product candidates, future
financial position, business strategy, new products, budgets,
liquidity, cash flows, projected costs, regulatory approvals, the
impact of any laws or regulations applicable to the Company, and
plans and objectives of management for future operations, are
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “should,” “estimate,” “expect,” “intend,” “may,”
“plan,” “project,” “will,” and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have
based these forward-looking statements on the current expectations
about future events held by management. While we believe these
expectations are reasonable, such forward-looking statements are
inherently subject to risks and uncertainties, many of which are
beyond the Company’s control. The Company’s actual future results
may differ materially from those discussed here for various
reasons. The Company discusses many of these risks under the
heading “Risk Factors” in the proxy statement/prospectus filed with
the SEC on June 10, 2021, as updated by the Company’s other filings
with the SEC.
Given these uncertainties, you should not place
undue reliance on these forward-looking statements. The
forward-looking statements included in this press release are made
only as of the date hereof. We do not undertake any obligation to
update any such statements or to publicly announce the results of
any revisions to any of such statements to reflect future events or
developments.
Contacts:Statera
BiopharmaNichol OchsnerExecutive V.P. Investor Relations
and Corporate Communications(732)
754-2545nichol.ochsner@staterabiopharma.com
FINN PartnersGlenn Silver (Media) (973)
818-8198glenn.silver@finnpartners.com
FINN PartnersDavid Carey (IR)(212)
867-1768David.carey@finnpartners.com
Statera BioPharma (NASDAQ:STAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Statera BioPharma (NASDAQ:STAB)
Historical Stock Chart
From Apr 2023 to Apr 2024